One possible mechanism for allograft rejection is the induction of T cells by donor and host antigen-presenting cells presenting allogeneic peptides. Host NK cells could play a pivotal role in ...

Unmodified natural killer (NK) cells work differently from the T-cells upon which CAR-T therapies are based – NKs are usually involved in killing cells that are infected with viruses, whereas T ...

New research has shown, however, that the lymphocytes – either T cells or NK cells, including the engineered NK cells – can ...

Recently, however, it was discovered that the lymphocytes, either T cells or NK cells, including "engineered" NK cells, can become fatigued from continuously battling tumors and subsequently lose ...

Mayra Shanley, PhD, discussed background and future directions for evaluating IL-21 natural killer cells for the treatment of ...

Recently, however, it was discovered that the lymphocytes, either T cells or NK cells, including "engineered" NK cells, can become fatigued from continuously battling tumors and subsequently lose ...

plus NK cell therapy being safer/tolerable] Lack thereof or no redosing option for patients who don't respond to Autologous CAR-T — The way that NKX019 acts as a NK cell therapy, it can easily ...

CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Leukemia.

The patent details methods of generating three-dimensional organoids capable of giving rise to hematopoietic cells, including precursors, and/or immune cells. This includes cells such as T cells, B ...

If this process is disrupted, it can lead to NK cells that don't function correctly. In the tumor microenvironment, when NK cells encounter a tumor, they are constantly stimulated.

CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for T-Cell Lymphomas.